Aurobindo Pharma has concluded its share buyback via a tender offer, extinguishing 0.54 Cr equity shares.

The buyback was executed at ₹1,475 per share, totaling up to ₹800 Cr.

This move reduces the company's total issued share capital from 58.08 Cr to 57.54 Cr shares, enhancing shareholder value.

The reduction in outstanding shares slightly increases earnings per share (EPS) for remaining shareholders.